<DOC>
	<DOC>NCT01208922</DOC>
	<brief_summary>The purpose of this study is to prove the non-inferiority of Rifamycin SV-MMX® versus Ciprofloxacin for the treatment of adults with traveller's diarrhoea.</brief_summary>
	<brief_title>Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Dysentery</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Rifamycin SV</mesh_term>
	<criteria>Informed consent, Signs or symptoms of indication of acute bacterial diarrhea (traveller's diarrhea) Fever, Grossly bloody stool, Females pregnant or breast feeding, Participation in an other clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>